CN105801510A - Medicine composition for treating depression - Google Patents
Medicine composition for treating depression Download PDFInfo
- Publication number
- CN105801510A CN105801510A CN201610220454.9A CN201610220454A CN105801510A CN 105801510 A CN105801510 A CN 105801510A CN 201610220454 A CN201610220454 A CN 201610220454A CN 105801510 A CN105801510 A CN 105801510A
- Authority
- CN
- China
- Prior art keywords
- compound
- depression
- pharmaceutical composition
- treatment
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CO[C@@](Cc1ccccc1)C(*)(CCCC1)C1=N Chemical compound CO[C@@](Cc1ccccc1)C(*)(CCCC1)C1=N 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to medicine composition for treating depression. The medicine composition is prepared from an effective dose of a compound and a pharmaceutically acceptable carrier, wherein the compound has the structure shown in the specification. The compound of the medicine composition can improves depression symptoms such as desperation, loss of pleasure, anxiety, sleep disorders and the like.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition treating depression.
Background technology
Depression is the main Types of affective disorders, is a kind of high prevalence, high burden, the high common mental sickness committed suiside, easily recur, easily disable, low for main manifestations with obvious and lasting mental state, can with corresponding thinking and behavior change.
The main clinical manifestation of depression is depressed, anhedonia, self-accusation, and self evaluation declines and weak etc., and nervimotion can be had sluggish or intense, how to decline with appetite and libido, early awakening and the symptom such as lose weight, and there is cognitive dysfunction simultaneously.Depression is the common mental sickness of a class serious harm human physical and mental health, the Disease Spectrum caused due to it constantly rises, the global disease burden joint study prediction of World Health Organization (WHO) (WHO), the Disease Spectrum of China's depression second largest Disease Spectrum source will be become, before will be located in malignant tumor, cardiovascular and cerebrovascular vessel and respiratory system disease to the year two thousand twenty depression.Asia mental sickness summit forum report display in 2005, the patients with depression of China has reached 26,000,000.In the whole world, the financial burden that depression causes accounts for the 4.4% of all Disease Spectrum, suitable with ischemic heart desease or diarrhoeal diseases.WHO points out simultaneously, and the maximum illness faced by the 21 century mankind is mental sickness, and depression is emphasis therein, and thinks that the risk of depression large-scale outbreak is 15%～20%.Therefore the pathogenesis of the hazardness an urgent demand researcher Study on Acceleration depression that depression is serious, and the antidepressant drug of exploitation better efficacy.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating depression.
In order to realize the purpose of the present invention, the present invention provides a kind of compound treating depression, and this compound has having structure:
The present invention also provides for a kind of pharmaceutical composition treating depression, and described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides for compound purposes in the medicine of preparation treatment depression, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character not eliminating compound as herein described, such as carrier or diluent.This kind of material is applied to individuality and is not resulted in undesirable biological action or not with harmful way and any component interaction in the compositions comprising it.
" pharmaceutically acceptable carrier " includes any and all of solvent as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, preservative (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, preservative, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
The compound of the present invention can improve the depressive symptoms such as despair, pleasant sensation forfeiture, anxiety and sleep disorder.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art's basic thought according to the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Cleaning grade male mice in kunming 40, weight (20.0 ± 2.0) g.
Modelling and administration
Chronic mild unpredictable stress stimulus is adopted to add lonely foster (Xu Jing, Li Xiaoqiu. the foundation of chronic stress depression model and evaluation [j] thereof. Chinese hehavioral medical science, 2003.12 (1): 14-17.) replicate depression mouse model, 3 groups of 30 mices of all the other except normal group are accepted the random stimulus of 5 weeks, including cold-wate swimming (4 DEG C, 5min), heat stress (45 DEG C, 5min), prohibit water (48h), fasting (48h), folder tail (1min), confine, electric shock vola (current intensity 1mA, continue 10s every time, between minor tick 1min, amount to 30 times), reverse 24h round the clock, rock that (speed is 1 s-1, 15min), adopt a kind of stimulation every day, average every kind of stimulation is used 3 times, and homologous stimulus can not occur continuously, makes animal can not expect the generation stimulated.Except matched group, each group mice starts gastric infusion on the 3rd week from modeling, and administration continues 21d, and administration time is some every afternoon 5, normal group and model group, gives normal saline gavage 1mL/500g body weight；Positive drug group, fluoxetine Hydrochloride 0.02g adds 1000mL normal saline and becomes suspension, gives gavage 1mL/500g body weight；The compounds of this invention group, the compound of 0.01g adds 1000mL normal saline and becomes suspension, gives gavage 1mL/500g body weight.
Tail suspension test
Tail suspension test is carried out after 36th afternoon administration 1h.Mouse tail is about 2cm place from end, being pasted and fixed on a horizon bar with medical proof fabric makes mice hang by the feet in open top container, head distance bottom 10cm, surrounding isolates animal sight line with plate, hanging 6min, after record, in 4min, mice adds up motionless (mice aloft stops struggling or the only having tiny limb motion) time is the disappointed time.Result is shown in following table.
| Group | The outstanding tail dead time (second) |
| Normal group | 42.81±13.12 |
| Model group | 151.62±24.82* |
| Positive drug group | 62.35±15.68Δ |
| The compounds of this invention group | 69.81±15.91Δ |
Compare with normal group, * P < 0.05；Compare with model group,ΔP<0.05
Comparing with normal group, the outstanding tail dead time of model group significantly raises, and represents modeling success；Comparing with model group, after treatment, each group outstanding tail dead time is decreased obviously, and illustrates to be respectively provided with therapeutic effect.
Claims (7)
1. the compound treating depression, it is characterised in that this compound has having structure:
2. the pharmaceutical composition treating depression, it is characterised in that described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of depression according to claim 2, it is characterised in that described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
4. the pharmaceutical composition for the treatment of depression according to claim 3, it is characterised in that described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of depression according to claim 4, it is characterised in that described diluent is lactose.
6. the pharmaceutical composition for the treatment of depression according to claim 3, it is characterised in that described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. compound purposes in the medicine of preparation treatment depression, it is characterised in that this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610220454.9A CN105801510A (en) | 2016-04-08 | 2016-04-08 | Medicine composition for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610220454.9A CN105801510A (en) | 2016-04-08 | 2016-04-08 | Medicine composition for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105801510A true CN105801510A (en) | 2016-07-27 |
Family
ID=56459899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610220454.9A Pending CN105801510A (en) | 2016-04-08 | 2016-04-08 | Medicine composition for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105801510A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798741A (en) * | 2017-02-07 | 2017-06-06 | 宫英 | A kind of pharmaceutical composition for treating depression |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1162957A (en) * | 1994-08-30 | 1997-10-22 | 三共株式会社 | Isoxazoles |
| EP1050303A2 (en) * | 1999-04-27 | 2000-11-08 | Pfizer Products Inc. | Methods and compositions for treating age-related behavioral disorders in companion animals |
| CN1642960A (en) * | 2002-04-02 | 2005-07-20 | 詹森药业有限公司 | Substituted amino isoxazoline derivatives and their use as anti-depressants |
| US20090076001A1 (en) * | 2005-04-07 | 2009-03-19 | Gruenenthal Gmbh | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments |
| CN102015664A (en) * | 2008-04-24 | 2011-04-13 | 埃比奥吉恩药物股份公司 | Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| CN102093387A (en) * | 2009-12-10 | 2011-06-15 | 天津药物研究院 | Crystal compound of 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridine-3-alcohol-hydrate |
-
2016
- 2016-04-08 CN CN201610220454.9A patent/CN105801510A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1162957A (en) * | 1994-08-30 | 1997-10-22 | 三共株式会社 | Isoxazoles |
| EP1050303A2 (en) * | 1999-04-27 | 2000-11-08 | Pfizer Products Inc. | Methods and compositions for treating age-related behavioral disorders in companion animals |
| CN1642960A (en) * | 2002-04-02 | 2005-07-20 | 詹森药业有限公司 | Substituted amino isoxazoline derivatives and their use as anti-depressants |
| US20090076001A1 (en) * | 2005-04-07 | 2009-03-19 | Gruenenthal Gmbh | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments |
| CN102015664A (en) * | 2008-04-24 | 2011-04-13 | 埃比奥吉恩药物股份公司 | Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one |
| CN102093387A (en) * | 2009-12-10 | 2011-06-15 | 天津药物研究院 | Crystal compound of 4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridine-3-alcohol-hydrate |
Non-Patent Citations (1)
| Title |
|---|
| KUI-YONG DONG ET AL: "Oxime-Mediated Oxychlorination and Oxybromination of Unactivated Olefins", 《EUROPEAN JOURNAL OF ORGANIC CHEMISTRY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798741A (en) * | 2017-02-07 | 2017-06-06 | 宫英 | A kind of pharmaceutical composition for treating depression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104367765A (en) | Traditional Chinese medicinal composition for treating depression as well as preparation method and application thereof | |
| CN202161075U (en) | Cervical vertebrae health care pillow | |
| CA2707114C (en) | Pharmaceutical compositions for treating depression and anxiety | |
| CN105725211A (en) | Food health product for improving sleep and preparation method thereof | |
| CN103432184A (en) | Application of great burdock fruit extract in drug production or foods | |
| CN102014931A (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN102228617B (en) | Medicinal composition for treating insomnia | |
| CN105801510A (en) | Medicine composition for treating depression | |
| CN103705774A (en) | Compound composition with effect of treating depression as well as preparation method and application thereof | |
| CN104223073A (en) | Food, health-care product or pharmaceutical composition for sleep aiding | |
| CN101450103A (en) | Medicine composition for treating hypochondria and anxiety neurosis | |
| CN104083357A (en) | Anti-depression medicine composition and application thereof | |
| CN103610858B (en) | The preparation method for the treatment of migraine, prosopalgic Chinese medicine composition | |
| CN106038522A (en) | Application of rhein in preparation of anti-depression medicines | |
| CN104490893B (en) | A kind of pharmaceutical composition of Cure for insomnia | |
| CN101947263B (en) | Medicament for treating neurasthenia and insomnia | |
| CN106798741A (en) | A kind of pharmaceutical composition for treating depression | |
| CN101066278B (en) | Medicine use of energy mixture | |
| CN105816460B (en) | A kind of pharmaceutical composition treating postpartum depression | |
| US11534425B2 (en) | Compounds for the treatment of acute organ injury | |
| CN103860578A (en) | Use of lentinan as antidepressant drug | |
| CN105878258A (en) | Application of acteoside to preparation of antidepressant drugs | |
| CN104784454A (en) | Traditional Chinese medicine for treating hyperthyroidism | |
| CN103316126A (en) | Traditional Chinese medicine for treating schizophrenia | |
| CN103919875A (en) | Method for preparing medicinal composition for treating hypochondria and anxiety |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160727 |
|
| WD01 | Invention patent application deemed withdrawn after publication |